Drug Approval | December 31, 2022
USFDA grants appeal for Ardelyx's XPHOZAH
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Having a healthy gut is key as it permits the body to build a stronger immune system
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
The new facility will be able to handle four times as many patients as the previous facility.
Cipla and Ethris partner for the development of mRNA-based therapies
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Subscribe To Our Newsletter & Stay Updated
